ENGINEERING NATURE’S OWN DELIVERY VEHICLE FOR POWERFUL ANTI-CANCER THERAPY

Tavec is developing the next-generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes.

Learn More →

Recent News

18Apr

THERILLIA acquires TAVEC Pharmaceutical and moves it to Montreal

Therillia Development Co., a Montreal-based subsidiary of Sanderling Ventures Canada, an investor in early-stage biotech companies, has acquired TAVEC Pharmaceuticals, the leading therapeutic exosome company.. Read More →
22Jun

Tavec and The Johns Hopkins University Complete Exosome Gene Therapy Worldwide Exclusive License

Tavec to further clinical development of miRNA loaded exosomes to treat cancer Exosome gene therapy platform allows highly-specific, targeted delivery of regulatory RNA to shut.. Read More →